

This listing of claims will replace all prior versions of claims in the application.

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Cancelled)

Claim 2. (Cancelled)

Claim 3. (Cancelled)

Claim 4. (Cancelled)

Claim 5. (Currently Amended)

Compounds according to Claim 1 selected from the

group A compound which is

N-(4-hydroxy-2-methoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-[1-(4-hydroxy-2-methoxyphenyl)ethylidene]- (3-hydroxyphenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(3-methoxyphenyl)acetohydrazide,
N-(3-fluoro-4-hydroxybenzylidene)phenylacetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(4-hydroxyphenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(3,4-dichlorophenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-m-tolylacetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-o-tolylacetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(2-chlorophenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(3-chlorophenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(4-fluorophenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(2-chloro-4-fluorophenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(3-fluorophenyl)acetohydrazide,
N-(4-hydroxybenzylidene)-(3-methoxyphenyl)acetohydrazide,
N-(4-hydroxy-2,6-dimethylbenzylidene)-(3-methoxyphenyl)acetohydrazide,
N-(3-fluoro-4-hydroxybenzylidene)-(3-methoxyphenyl)acetohydrazide,
N-[1-(4-hydroxy-2-methoxyphenyl)ethylidene]- (3-methoxyphenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(3-methylsulfonyloxyphenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(3,5-dihydroxyphenyl)acetohydrazide,
N-(3-fluoro-4-hydroxybenzylidene)-(3-fluorophenyl)acetohydrazide,

N-(4-acetoxy-2-methoxybenzylidene)-(3-methoxyphenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(3-trifluoromethylphenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-3-(3-methoxyphenyl)propiohydrazide,
N-(2,4-dihydroxybenzylidene)-(3-methoxyphenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(3-methoxyphenoxy)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(3-nitrophenyl)acetohydrazide,
N-(5-chloro-2-hydroxybenzylidene)-(3-methoxyphenyl)acetohydrazide,
N-(2-hydroxy-5-nitrobenzylidene)-(3-methoxyphenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-2-hydroxy-2-phenylacetohydrazide,
N-(2-ethoxy-4-hydroxybenzylidene)-(3-methoxyphenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(3-bromophenyl)acetohydrazide,
N-[1-(4-hydroxyphenyl)ethylidene]-(3-methoxyphenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(3,5-difluorophenyl)acetohydrazide,
N-(4-hydroxy-2-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-ethoxy-4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-methoxy-4-hydroxy-6-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-methoxy-4-hydroxybenzylidene)-(2-fluorophenyl)acetohydrazide,
N-(2,4-dihydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-5-chlorobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(4-methylsulfonylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2,6-dimethyl-4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-methoxy-4-hydroxybenzylidene)-(3-hydroxy-4-methoxyphenyl)acetohydrazide,
N-(2-methoxy-4-hydroxybenzylidene)-(2,3-dimethoxyphenyl)acetohydrazide,
N-(2-methoxy-4-hydroxybenzylidene)-(3-aminophenyl)acetohydrazide,
N-(2,4-dihydroxy-6-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-methoxy-4-hydroxybenzylidene)-(2-methyl-3-methoxyphenyl)acetohydrazide,
N-(4-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(4-iodobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-bromo-5-chlorobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-5-tert-butylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-5-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2-hydroxy-5-trifluoromethoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-methoxy-5-nitrobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(4-hydroxy-2-methoxybenzylidene)-(3-ethoxyphenyl)acetohydrazide,
N-(2-hydroxy-3,5-dichlorobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-5-iodobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-methyl-5-chlorobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-5-fluorobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-6-methylbenzylidene)-(3,5-difluorophenyl)acetohydrazide,
N-(2-hydroxy-6-methylbenzylidene)-(3-fluorophenyl)acetohydrazide,
N-(2-hydroxy-6-methylbenzylidene)phenyl acetohydrazide,
N-[1-(4-hydroxyphenyl)ethylidene]-(3-hydroxyphenyl)acetohydrazide,
N-[1-(2,4-dihydroxyphenyl)ethylidene]-(3-hydroxyphenyl)acetohydrazide,
N-(2,4-dihydroxy-6-methylbenzylidene)-(3-methyl-5-methoxyphenyl)acetohydrazide,
N-(2,4-dihydroxy-6-methylbenzylidene)-(3,5-dihydroxyphenyl)acetohydrazide,
N-(2-hydroxy-4-carboxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2,3-dimethyl-4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(3,5-di-tert-butyl-4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(3,5-dimethyl-4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-acetoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-methoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-5-methoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-5-nitrobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-nitrobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-6-methoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-5-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(3-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-tert-butylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-4-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-nitro-5-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,

N-(2-hydroxy-4-methyl-5-chlorobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2,6-dimethoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-fluorobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-bromo-5-nitrobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-6-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-4-methoxy-6-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-4-acetoxy-6-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-4-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(3-chloro-4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-bromo-5-methoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2,4,6-trimethylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(3,5-dibromo-4-hydroxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2,4,5-trimethoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-methoxy-5-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(4-hydroxy-3-ethoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-methoxy-4-nitrobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(-(4-hydroxy-3-carboxybenzylidene)-3-hydroxyphenyl)acetohydrazide,
N-(2-hydroxy-3-methoxy-5-bromobenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(4-carboxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2,4-dimethylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2-methylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(4-trifluoromethylbenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(4-trifluoromethoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,
N-(2,4-dihydroxy-6-methylbenzylidene)-(3-hydroxy-5-methylphenyl)acetohydrazide,
N-(2,4-dihydroxy-6-methylbenzylidene)-(3-hydroxy-2-methylphenyl)acetohydrazide, or
N-(2-hydroxy-4,6-dimethoxybenzylidene)-(3-hydroxyphenyl)acetohydrazide,

and the or a pharmaceutically acceptable prodrug, salt, solvate or stereoisomer thereof or a mixture ~~usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof~~ in all ratios.

Claim 6. (Currently Amended)

Medicaments A pharmaceutical composition

comprising at least one compound according to Claim 4 5 and pharmaceutically acceptable carrier or vehicle and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

Claim 7. (Withdrawn, Currently Amended) Use of compounds according to Claim 1 and the pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or prophylaxis of diseases in which the inhibition, regulation and/or modulation of A method for modulating a protein kinase signal transduction comprising contacting said kinase with a compound of claim 5 by kinases plays a role.

Claim 8. (Withdrawn, Currently Amended) Use The method according to Claim 7, where wherein the kinase is serum and glucocorticoid dependent kinase (SGK) SGK.

Claim 9. (Withdrawn, Currently Amended) Use The method according to Claim 8 comprising inhibiting the activity of said SGK for the treatment of diseases which are influenced by inhibition of SGKs by the compounds.

Claim 10. (Withdrawn, Currently Amended) Use according to Claim 9 for the preparation of a medicament A method for the treatment or prevention of diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertension, cardiovascular disease, diseases and renal disease diseases, generally in any type of fibrosis and or inflammatory process, cancer, tumour cells, tumour metastases, coagulopathy coagulopathies, neuronal excitability, glaucoma, cataract, bacterial infection, or a method for infections and in antiinfection therapy, for or increasing learning ability and attention comprising administering to a subject in need thereof a compound of claim 5.

Claim 11. (Withdrawn, Currently Amended) Use The method according to Claim 10, where wherein the diabetes is diabetes mellitus, diabetic nephropathy, diabetic neuropathy, diabetic angiopathy and or microangiopathy.

Claim 12. (Withdrawn, Currently Amended) Use The method according to Claim 10,

~~where wherein the cardiovascular disease is diseases are~~ cardial fibroses after myocardial infarction, cardiac hypertrophy, cardiac insufficiency ~~and or~~ arteriosclerosis.

Claim 13. (Withdrawn, Currently Amended) Use The method according to Claim 10, ~~where wherein the renal disease is diseases are~~ glomerulosclerosis, nephrosclerosis, nephritis, nephropathy ~~and or~~ electrolyte excretion disorder.

Claim 14. (Withdrawn, Currently Amended) Use The method according to Claim 10, ~~where wherein the fibrosis and or inflammatory processes process comprises~~ liver cirrhosis, pulmonary fibrosis, fibrosing pancreatitis, rheumatism and arthrosis, Crohn's disease, chronic bronchitis, radiation fibrosis, sclerodermatitis, cystic fibrosis, scarring ~~and or~~ Alzheimer's disease.

Claim 15. (Currently Amended) ~~Medicaments~~ A medicament comprising at least one compound according to Claim ~~4 5 together with an excipient or an adjuvant and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.~~

Claim 16. (Currently Amended) ~~Set (kit) consisting of separate packs of~~ A kit comprising

- (a) ~~an effective amount of a first package comprising~~ a compound according to Claim ~~4 5 or a pharmaceutical composition thereof and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,~~
- and
- (b) ~~a second package comprising~~ an effective amount of a further medicament active ingredient.

Claim 17. (New) The compound of claim 5 which is in E stereoisomer configuration.

Claim 18. (New) The prodrug compound of claim 5 which comprises a cleavable alkyl, acyl, sugar or oligopeptide group or a biodegradable polymer.

Claim 19. (New) A process for the synthesis of a compound of claim 5 comprising

hydrazonation.

Claim 20. (New) The method of claim 8 wherein said SGK is sgk-1.

Claim 21. (New) A method of inhibiting tumor growth and/or metastasis in a subject comprising administering to said subject an effective amount of at least one compound of claim 5.

Claim 22. (New) The method of claim 21 wherein said tumor is sensitive to SGK inhibition.